Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by SABBOBCATon Dec 02, 2022 10:21am
218 Views
Post# 35146183

Pivot to NASH

Pivot to NASH

With 20/20 hindsight we can now see that they pivot to NASH and Trogarzo chat during the Q3 call was already the start of a realignment. My blind optimisim was hoping they were looking to make a big splash, and in a way that was true, but they were jumping into the swamp instead of the refreshing pool. 

Now, the question becomes, "was Paul's 'Posisition of Strength' talk regarging NASH negotions all hot air?'. I certainly hope not, but that is the short term upside for this stock now. There will be continued selling as some look to redeploy capital, while others will hold to wait and see what the new protocol looks like in the new year, but reality is without a partnerhip deal we are now dead in the water. Lets home the earlier pivot and NASH focused speaking engagements bring with it some positives.

FML, it feels like late 2019 again now. Please let's not relive 2020 LOL

<< Previous
Bullboard Posts
Next >>